ESPR vs REGN
ESPR: Esperion commercializes NEXLETOL and NEXLIZET, first-in-class non-statin ACLY inhibitors proven to reduce cardiovascular risk in statin-intolerant or statin-unwilling patients with elevated cholesterol. REGN: Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas.
Side-by-side fundamentals
| Metric | ESPR | REGN | Edge |
|---|---|---|---|
| Price as of 2026-07-13 close | $3.18 | $651.18 | |
| Market cap as of 2026-07-23 | $819M | $70.6B | |
| P/E as of 2026-07-23 | n/a | 15.95 | |
| PEG as of 2026-07-23 | n/a | 1.01 | |
| Net margin as of 2026-07-23 | -1.8% | +29.6% | REGN higher |
| Gross margin as of 2026-07-23 | +68.4% | +85.7% | REGN higher |
| Operating margin as of 2026-07-23 | +18.1% | +24.3% | REGN higher |
| ROE as of 2026-07-23 | -59.5% | +14.3% | REGN higher |
| ROA as of 2026-07-23 | -1.8% | +11.1% | REGN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.09 | ESPR lower |
| Revenue growth (YoY) as of 2026-07-23 | +61.1% | +5.9% | ESPR higher |
| Revenue CAGR (3y) SEC XBRL | +74.8% | +5.6% | ESPR higher |
| Dividend yield as of 2026-07-23 | n/a | +0.6% | |
| Beta as of 2026-07-23 | 1.15 | 0.21 | |
| 1-year return as of 2026-07-13 close | +156.5% | +16.1% | ESPR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-13.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.